Loré F, Di Cairano G, Signorini A M, Caniggia A
Calcif Tissue Int. 1981;33(5):467-70. doi: 10.1007/BF02409475.
Serum concentrations of 25-hydroxy-vitamin D were measured in a group of women with symptomatic postmenopausal osteoporosis, assessed by bone biopsy. A competitive protein binding assay was used, which included a chromatographic step. Accurate surveys of dietary or therapeutic vitamin D intake and light environment were obtained in each patient. Women with severe postmenopausal osteoporosis were found to have significantly (P less than 0.001) higher serum levels of 25-hydroxyvitamin D than age-matched normal women, the mean values being 27.5 ng/ml (+/- 13.6 SD) and 9.2 ng/ml (+/-5.7), respectively. The authors hypothesize that the reduction in 1,25-dihydroxyvitamin D, recently reported in postmenopausal osteoporotic women, might be responsible for the increased serum levels of 25-hydroxyvitamin D through an inadequate product inhibition of liver vitamin D 25-hydroxylase.
通过骨活检评估了一组有症状的绝经后骨质疏松症女性的血清25-羟维生素D浓度。采用了一种竞争性蛋白结合测定法，其中包括一个色谱步骤。对每位患者的饮食或治疗性维生素D摄入量以及光照环境进行了准确调查。发现患有严重绝经后骨质疏松症的女性血清25-羟维生素D水平显著高于年龄匹配的正常女性（P<0.001），平均值分别为27.5 ng/ml（±13.6标准差）和9.2 ng/ml（±5.7）。作者推测，最近在绝经后骨质疏松症女性中报道的1,25-二羟维生素D减少可能是由于对肝脏维生素D 25-羟化酶的产物抑制不足，从而导致血清25-羟维生素D水平升高。
